anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Body weight is an important economic trait for sheep meat production, and its genetic improvement is considered one of the main goals in the sheep breeding program. Identifying genomic regions that are associated with growth-related traits accelerates the process of animal breeding through marker-assisted selection, which leads to increased response to selection. In this study, we conducted a weighted single-step genome-wide association study (WssGWAS) to identify potential candidate genes for direct and maternal genetic effects associated with birth weight (BW) and weaning weight (WW) in Baluchi sheep. The data used in this research included 13,408 birth and 13,170 weaning records collected at Abbas-Abad Baluchi Sheep Breeding Station, Mashhad-Iran. Genotypic data of 94 lambs genotyped by Illumina 50K SNP BeadChip for 54,241 markers were used. The proportion of variance explained by genomic windows was calculated by summing the variance of SNPs within 1 megabase (Mb). The top 10 window genomic regions explaining the highest percentages of additive and maternal genetic variances were selected as candidate window genomic regions associated with body weights. Our findings showed that for BW, the top-ranked genomic regions (1 Mb windows) explained 4.30 and 4.92% of the direct additive and maternal genetic variances, respectively. The direct additive genetic variance explained by the genomic window regions varied from 0.31 on chromosome 1 to 0.59 on chromosome 8. The highest (0.84%) and lowest (0.32%) maternal genetic variances were explained by genomic windows on chromosome 10 and 17, respectively. For WW, the top 10 genomic regions explained 6.38 and 5.76% of the direct additive and maternal genetic variances, respectively. The highest and lowest contribution of direct additive genetic variances were 1.37% and 0.42%, respectively, both explained by genomic regions on chromosome 2. For maternal effects on WW, the highest (1.38%) and lowest (0.41%) genetic variances were explained by genomic windows on chromosome 2. Further investigation of these regions identified several possible candidate genes associated with body weight. Gene ontology analysis using the DAVID database identified several functional terms, such as translation repressor activity, nucleic acid binding, dehydroascorbic acid transporter activity, growth factor activity and SH2 domain binding.
PURPOSE:To obtain a ribosome having good retentivity in blood and good intake into a parenchyma cell of liver and improved in stability. CONSTITUTION:A ribosome coated with sterol (S) and/or sterolglucoside (SG), e.g. diparmitoylphosphatidyl choline ribosome. As S, one or more sterol derivatives selected from sitosterol, campesterol, stigmasterol and brassicasterol are used and as SG, one or more compounds selected from glucoside corresponding to the sterol are used. S ribosome has good retentivity in blood and SG ribosome has good intake into a parenchyma cell of liver. Consequently, when the ribosome is used as a medicine carrier, S ribosome is effective in sustained release of the medicine and SC ribosome is effective in targeting liver.
This study is an open-label, single-arm, Phase II, PK and pharmacodynamic (PD) trial of CPX-351 in patients with documented acute leukemia (AML or ALL) or MDS (IPSS score ≥ 1.5) and suitable for treatment with intensive chemotherapy. Each patient will be screened for hepatic impairment. Hepatic impairment will be assessed using the Child-Pugh system and only patients with a Child-Pugh score \<7 points will be eligible for this study. Patients will receive up to two inductions and four consolidation courses. Patients will be monitored for safety (early deaths, adverse events, metabolic changes, etc.) and efficacy (response for AML, ALL, and MDS) while on the study.
The carcinogenicity of beclomethasone dipropionate was evaluated in rats which were exposed for a total of 95 weeks, 13 weeks at inhalation doses up to 0.4 mg/kg/day and the remaining 82 weeks at combined oral and inhalation doses up to 2.4 mg/kg/day. There was no evidence of carcinogenicity in this study at the highest dose, which is approximately 30 and 55 times the maximum recommended daily inhalation dose in adults and children, respectively, on a mg/m2 basis.

Beclomethasone dipropionate did not induce gene mutation in the bacterial cells or mammalian Chinese Hamster ovary (CHO) cells in vitro. No significant clastogenic effect was seen in cultured CHO cells in vitro or in the mouse micronucleus test in vivo.

In rats, beclomethasone dipropionate caused decreased conception rates at an oral dose of 16 mg/kg/day (approximately 200 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). Impairment of fertility, as evidence by inhibition of the estrous cycle in dogs, was observed following treatment by the oral route at a dose of 0.5 mg/kg/day (approximately 20 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). No inhibition of the estrous cycle in dogs was seen following 12 months of exposure to beclomethasone dipropionate by the Inhalation route at an estimated daily dose of 0.33 mg/kg (approximately 15 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis).
Cystic fibrosis (CF) is a life-limiting multi-system disease primarily characterized by chronic lung infections and pulmonary symptoms such as cough, dyspnea, and chest tightness. Those with CF rely on numerous pharmaceutical and treatment-based therapies as part of their routine care to maintain lung health. Airway clearance, one such treatment-based therapy, uses breathing techniques and various vibrating devices to mobilize lung secretions and is considered a cornerstone of CF care. Vest therapy, a "shaking vest" that applies pressure and high frequency vibrations to the chest wall is the most commonly used technique for airway clearance in the U.S., but adherence to recommended goals for airway clearance is low. Barriers to adherence include the time limitations and unclear goal setting for effective treatment. A previous pilot study by this research team showed that CF patients find the use of airway clearance vests equipped with both pre-set and individually determined programing capabilities as well as electronic monitoring and transmitting capabilities to be acceptable and feasible. Information such as vest-use time, vest pressure measures, programming choices and symptom reporting is captured by these devices and transmitted to health care teams for review as well as provided to patients to provide feedback on treatment goals. This study aims to determine if providing patients with clearly stated treatment goals and the means to monitor and receive positive reinforcing feedback on vest use through interactive technology (i.e. virtual coaching) will improve vest therapy adherence in individuals with CF.
The invention belongs to the field of medicine, and particularly relates to a gatifloxacin dispersible tablet and a preparation method of the gatifloxacin dispersible tablet. The invention aims to provide the gatifloxacin dispersible tablet, so that the medicine is highly dispersed, the disintegration of the tablet and the dissolution of the effective components are accelerated, and the product stability and bioavailability are improved. The dispersible tablet is prepared from the following components (shown in the specification) by weight ratio. The dispersing tablet is obtained by preparing gatifloxacin and a carrier of the solid dispersion into solid dispersion through a solid dispersion technology, and then mixing with other adjuvants, and tabletting. According to the invention, the gatifloxacin dispersible tablet for highly dispersing the medicines can be obtained by the prescription, steps and parameter control, so that the disintegration of the tablet and the dissolution of the effective components are accelerated and the product stability and bioavailability are improved. The preparation method is simple and feasible, and the technology does not have special requirements on the device, so that the gatifloxacin dispersible tablet is suitable for mass production.
Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
Scaling is a common procedure performed by general dental practitioners and dental specialists. Unfortunately, scaling has been associated with unpleasant dental treatment and to some extent, a painful experience (Berggren \& Meynert, 1984). Studies also have demonstrated that scaling using ultrasonic scalers can cause tooth surface roughness and tooth substance loss (Jepsen et al., 2004; Kawashima et al., 2007). Rough tooth surface will increase retention of plaque and has been shown associated with early biofilm formation (Teughels et al., 2006). Subsequently, this would increase the risk for development and progression of periodontal disease. Whereas, tooth substance loss may lead to exposed dentinal tubules, and subsequently root sensitivity. Root sensitivity was reported to affect half of patients receiving periodontal therapy (Von Troil et al., 2002). This led to discomfort among patients and avoidance to dental treatment in future.

Advanced development in scaler tip designs has provided opportunities to deliver scaling treatment that is less aggressive to tooth surfaces and most importantly, to reduce the discomfort to patients. The design of the scaler tip has influenced the performance of ultrasonic scalers characterised by the displacement amplitude (Lea et al., 2003b). Displacement amplitude is the lateral movement of scaler tip that is thought to contribute to the aggressiveness of scaling procedure. Several studies have investigated the factors that may influence displacement amplitude, such as power setting and type of generator (Lea et al., 2003a), tip wear (Lea et al., 2006) and scaler tip designs (Lea et al., 2003a). However, to date, there were limited studies that investigated the effect of ultrasonic scaler tip design particularly slim and wide scaler tip on tooth surface roughness, tooth substance loss, and patients' pain perception.

In a clinical setting, if there were two treatment methods that provide similar levels of effectiveness but different levels of discomfort and damage to tooth surface patient will opt for the more comfortable and conservative method. Therefore, this study investigated the influence of scaler tip designs on tpatients' pain perception following scaling.
BACKGROUND: The aims of this analysis were: to evaluate the impact of timing of ablation on the rate of atrial arrhythmias recurrence, verify if the timing of ablation impact differently in patients with paroxysmal and persistent AF.
METHODS: Three thousand two hundred and five patients (60.5 ± 10 years, female 28.4%%, 78.8%% paroxysmal AF) were included in the analysis. All patients underwent only cryoballoon (CB) pulmonary vein (PV) isolation during the index procedure.
RESULTS: The mean procedure time was 102.8 ± 50 min, with a mean fluoroscopy time of 26.3 ± 49 min. Acute PV isolation was achieved in 11760/11793 (99.7%) PVs. A total of 91 (2.8%) patients experienced a procedure-related complication. During the observation period 913/3205 (28.5%) patients had at least one atrial arrhythmias episode: 28% of patients with paroxysmal AF vs 33% of patients with persistent AF. In multivariate analysis, persistent AF together with time from symptomatic AF diagnosis to ablation, female sex, and ablation time showed to be significant predictors for AF recurrence. In particular, months from first symptomatic AF episode > 18 months was a significant predictor of AF recurrence (HR = 1.23, 95% CI = 1.03-1.46, p = 0.020). In patients with paroxysmal AF, the multivariate analysis confirmed that months from first symptomatic AF episode > 18 month was an independent predictor of AF recurrence together with age > 62 years and female sex. In patients with persistent AF, the time from persistent AF showed to be significant predictor for AF recurrence.
CONCLUSIONS: In this multicenter analysis, time from first symptomatic AF episode > 18 months was a significant predictor of AF recurrence after CB PV isolation.
Study of standard adjuvant capecitabine in stage I to III TNBC with less than a pCR. This Arm will be open in parallel with both Phases 1 and 2. Blood samples will be obtained during the course of the study. Bone marrow samples are optional.
PURPOSE:To provide an agent to promote the absorption of vitamin E administered to man, domestic animal and domestic fowl, by using Clostridium butyricum Miyairi as an active component. CONSTITUTION:Clostridium butyricum Miyairi is used as an active compound of the titled agent. Clostridium butyricum Miyairi is an anti-putrefactive butyric bacillus known as Miyairi bacillus having the shape of straight of slightly curved rod with blunt ends at both sides. It can be administered together with vitamin E to promote the absorption and improve the pharmacological effect of the vitamin. The intestinal absorption of vitamin E can be promoted with the present agent even in the case of the administration of vitamin E orally as a solid drug. The Miyairi bacillus is added preferably in an amount of 10-2,000mg to 1kg of feed.
The safety and efficacy of Ioflupane I 123 Injection were evaluated in two multicenter, single-arm, open-label studies (Study 1 and Study 2) that enrolled 284 adult patients with suspected PS. 

In these studies, Ioflupane I 123 Injection image interpretation was compared to a reference clinical diagnostic standard of "PS" or "non-PS". PS consisted of Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). These conditions have been associated with dopaminergic neurodegeneration and Ioflupane I 123 Injection imaging was not designed to distinguish among the conditions. Among the non-PS population, subjects with a history of the following conditions were included: vascular parkinsonism, psychogenic parkinsonism, essential tremor (ET), various forms of tremor, and other non-PS diagnoses; Ioflupane I 123 Injection imaging was not designed to distinguish among these conditions. 

Patients underwent SPECT imaging with a variety of multi-headed cameras or multi-detector single- slice systems 3 to 6 hours after Ioflupane I 123 Injection administration. The Ioflupane I 123 Injection activity in these two clinical studies ranged from 111 MBq to 201 MBq (3 mCi to 5.4 mCi) [median 167.8 MBq (4.5 mCi)]. Readers blinded to clinical information interpreted Ioflupane I 123 Injection imaging as normal or abnormal [see Dosage and Administration (2.7)]. A normal image is inconsistent with clinical conditions associated with PS and an abnormal image is consistent with clinical conditions associated with PS.

Study 1 consisted of 99 patients with early features of Parkinsonism; patients with features suggestive of MSA or PSP were excluded. The baseline clinical diagnoses consisted of: probable PD (44%), possible PD (31%), “benign” PD (6%), possible ET (11%), and other diagnoses (7%). The patients were 44% female, 42% of age 65 years or over, and all were White. Study 1 readers had no other role in patient assessment. The reference clinical diagnostic standard consisted of the clinical diagnoses established by a consensus panel of movement disorder specialists that evaluated data inclusive through 36 months of follow-up.

Study 2 consisted of 185 patients with clinically established diagnosis of PS (PD, MSA, PSP) or ET. The baseline clinical diagnoses consisted of: PD (70%), MSA (10%), PSP (5%), and ET (15%). The patients were 35% female, 48% of age 65 years or over, and 99% were White. Study 2 readers included site investigators. The reference clinical diagnostic standard consisted of the investigator-determined baseline clinical diagnosis. 

Table 4 shows the positive percent agreement and negative percent agreement of the Ioflupane I 123 Injection image results with the reference clinical diagnostic standard. Positive percent agreement represents the percent of patients with abnormal Ioflupane I 123 Injection images among all the patients with a clinical diagnostic reference standard of PS. Negative percent agreement represents the percent of patients with normal Ioflupane I 123 Injection images among the patients with a non-PS clinical diagnostic reference standard.
Anterior cruciate ligament (ACL) tears have a recovery time of nearly 6-12 months with operative treatment. While most service members return to full duty after ACL reconstruction, it is delayed by quadriceps activation, muscle weakness, and abnormal gait patterns. Neuromuscular electric stimulation devices are already being used in physical therapy to complement gains in muscle strength and size. The innovation of KneeStim, is that it can be used to stimulate knee muscles while the individual is engaging in their daily activities. This study looks at the effects of 12 weeks of post-operative use of the KneeStim on biomechanical function (gait) in United States Military Academy Cadets aged 17-27 years of age. The investigators hypothesize that using the KneeStim will accelerate normalization of the biomechanical function parameters of gait and thus return to full duty.
All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
A pharmaceutical composition suitable for use with a metered dose inhaler (MDI) comprises (1). A drug component comprising at least one tiotropium compound selected from tiotropium and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1- difluoroethane (HFA-152a). Preferably, the tiotropium compound is tiotropium bromide or tiotropium bromide monohydrate. Preferably, the composition also contains a long acting beta-2-agonist (LABA) (e.g. formoterol, salmeterol, olodaterol). Preferably, the composition also contains a corticosteroid (e.g. budesonide, mometasone, beclomethasone, fluticasone). Preferably, the composition comprises a surfactant (e.g. PVP, polyethylene glycol (PEG), oleic acid, lecithin). The composition may contain a polar excipient such as ethanol. Most preferably, the composition contains less than 5 ppm water. It is claimed that the use of HFA-152a increases the stability, and aerosolisation performance after storage, of the composition relative to the use of other HFA compounds.
Activated microglia and their mediated inflammatory responses play an important role in the pathogenesis of hypoxic-ischemic brain damage (HIBD). Therefore, regulating microglia activation is considered a potential therapeutic strategy. The neuroprotective effects of gastrodin were evaluated in HIBD model mice, and in oxygen glucose deprivation (OGD)-treated and lipopolysaccharide (LPS)activated BV-2 microglia cells. The potential molecular mechanism was investigated using western blotting, immunofluorescence labeling, quantitative realtime reverse transcriptase polymerase chain reaction, and flow cytometry. Herein, we found that PI3K/AKT signaling can regulate Sirt3 in activated microglia, but not reciprocally. And gastrodin exerts anti-inflammatory and antiapoptotic effects through the PI3K/AKT-Sirt3 signaling pathway. In addition, gastrodin could promote FOXO3a phosphorylation, and inhibit ROS production in LPSactivated BV-2 microglia. Moreover, the level P-FOXO3a decreased significantly in Sirt3-siRNA group. However, there was no significant change after gastrodin and siRNA combination treatment. Notably, gastrodin might also affect the production of ROS in activated microglia by regulating the level of P-FOXO3a via Sirt3. Together, this study highlighted the neuroprotective role of PI3K/AKT-Sirt3 axis in HIBD, and the anti-inflammatory, anti-apoptotic, and anti-oxidative stress effects of gastrodin on HIBD.
A 104-week rat inhalation toxicology study to assess the carcinogenic potential of aztreonam demonstrated no drug-related increase in the incidence of tumors. Rats were exposed to aerosolized aztreonam for up to 4 hours per day. Peak plasma levels of aztreonam averaging approximately 6.8 mcg/mL were measured in rats at the highest dose level. This is approximately 12-fold higher than the average peak plasma level measured in humans following CAYSTON therapy.

Genetic toxicology studies performed in vitro demonstrated that aztreonam did not induce structural chromosome aberrations in CHO cells and did not induce mutations at the TK locus in mouse lymphoma L5178Y TK+/- cells. In vivo, aztreonam was not clastogenic in mouse bone marrow cells.

Aztreonam did not impair the fertility of rats when administered parenterally at doses up to 2400 mg/kg/day that would provide systemic exposures significantly higher than peak plasma levels measured in humans following CAYSTON therapy.
In the intervention group, endometrial sampling is obtained twice by Pipelle \[one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle\]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
Titratable matched placebo candesartan one tablet twice daily + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
Patients with non-valvular atrial fibrillation who are at risk for stroke and non-central nervous system (non-CNS) systemic embolism, will be randomized (assigned by chance) to receive treatment with rivaroxaban or warfarin, two different anticoagulants (substances that prevent blood clots). Treatment will be double-blinded (neither the patient nor study staff will know which study drug is assigned to patients during the study). Patients assigned to rivaroxaban will receive rivaroxaban 20 mg orally (p.o.) once daily (OD) plus warfarin placebo p.o. OD titrated to a target sham international normalized ratio (INR) of 2.5. Patients with moderate renal impairment at screening will receive rivaroxaban 15 mg p.o. OD. Patients assigned to warfarin will receive warfarin p.o. OD titrated to a target INR of 2.5 plus rivaroxaban placebo p.o. OD. The maximum expected length of treatment is up to 32 months but may be extended up to 4 years.
The invention relates to a beneficial bacteria antibacterial foam spraying agent. The invention has a technical scheme that the agent is prepared from the raw materials of, by weight: 0.5-1% of lactic acid bacteria, 2-4% of lactic acid, 0.4-1.5% of lactobacillus, 10-20% of glycerol, 2-5% of hydrogenated castor oil (L-23), 5-7% of 1-vinyl-2-pyrrolidone (K-30), 6-9% of tetrafluoroethane (134a), and 60-65% of purified water. The raw materials are subjected to main processes such as culturing, blending, and filling, such that the foam spraying agent is prepared. The foam spraying agent is antibacterial, and has the function of beneficial flora regulating. The agent has protecting, maintaining, health-caring, and cleaning functions upon women genitals. The product provided by the invention is a foam spraying agent, such that the product has the characteristics of small dosage and fast absorption.